Trigeminal neuralgia (TN) is a disorder characterized by sudden-onset, extremely severe, electric shock-like facial pain occurring within the distribution of the trigeminal nerve (cranial nerve V). It is regarded as one of the most severe pain syndromes encountered in clinical medicine. The estimated annual incidence is approximately 4-5 cases per 100,000 population, with a prevalence of approximately 15-20 per 100,000.
Women are affected more frequently than men (approximately 1.7:1), and the incidence increases particularly after the age of 50 years.
The trigeminal nerve emerges from the pons and divides into three major branches:
Trigeminal neuralgia is unilateral in approximately 95% of cases. Bilateral facial pain should raise particular concern for a secondary cause, especially multiple sclerosis, and warrants prompt MRI evaluation.
Pain-free remission may persist for months or even years and is particularly characteristic of classical trigeminal neuralgia.
Differential diagnosis: dental pain. Patients with trigeminal neuralgia are frequently initially treated for presumed dental disease and may undergo unnecessary dental procedures or tooth extractions. The characteristic brief, electric shock-like paroxysms and their reproducible triggering by innocuous stimuli are key diagnostic features.
The diagnosis of trigeminal neuralgia is primarily clinical. A detailed pain history - including pain quality, anatomical distribution, triggers, attack duration, and frequency - is essential.
High-resolution cranial MRI is the key imaging investigation. Dedicated sequences such as CISS/FIESTA, together with contrast-enhanced T1-weighted imaging, permit detailed evaluation of the trigeminal nerve and adjacent structures.
Treatment of trigeminal neuralgia follows a stepwise approach ranging from pharmacological management to interventional and neurosurgical procedures. The choice of treatment depends on the type of trigeminal neuralgia, the patient's general medical condition, neuroimaging findings, and the response to previous therapies.
Treatment efficacy may diminish over time, while adverse effects such as dizziness, somnolence, and hyponatremia may limit long-term pharmacological therapy.
Stereotactic radiosurgery uses a highly focused radiation dose to modulate trigeminal nerve function, typically targeting a short segment of the cisternal trigeminal nerve near the brainstem. The biological effect is thought to involve focal axonal and myelin changes that reduce pathological pain transmission while preserving surrounding critical structures as far as possible.
For radiosurgical treatment of trigeminal neuralgia, a short segment of the trigeminal nerve in the prepontine cistern is precisely defined as the radiosurgical target. CyberKnife and ZAP-X permit highly conformal dose delivery from multiple beam directions without invasive frame fixation. Dose constraints are applied rigorously to minimize radiation exposure to adjacent critical structures, particularly the brainstem and cochlea.
Unlike microvascular decompression or percutaneous rhizotomy, the effect of CyberKnife radiosurgery is not immediate. Pain relief typically begins within approximately 2-8 weeks, although some patients may not experience a meaningful response until 3-6 months after treatment. Published series report substantial or complete pain reduction in approximately 70-90% of patients during the first 6 months. This delayed onset of action is an important aspect of patient counseling.
A substantial proportion of patients remain pain-free or significantly improved for several years after radiosurgery. Recurrence may occur and is generally more frequent than after successful microvascular decompression. In selected patients, an important advantage of radiosurgery is that repeat treatment may be considered if clinically appropriate.
Both treatments aim to modify pathological pain transmission within the trigeminal system, but they differ fundamentally in technique. Percutaneous rhizotomy - including balloon compression or radiofrequency thermocoagulation - generally provides immediate pain relief and is performed under anesthesia or deep sedation, but facial numbness and other sensory disturbances occur more frequently. Radiosurgery is completely non-invasive and requires no general anesthesia, but its therapeutic effect is delayed. Sensory dysfunction may occur after either procedure, although the risk profile differs according to technique and dose.
Usually not. Pharmacological treatment for trigeminal neuralgia is generally continued during and immediately after radiosurgery. Once a sustained therapeutic effect has developed over the following weeks or months, medication may be gradually reduced if clinically appropriate. Any dose adjustment should be coordinated closely with the treating neurologist.
Radiosurgery is an established treatment option for selected patients with trigeminal neuralgia associated with multiple sclerosis. In this setting, pain may be related to demyelinating lesions involving trigeminal pathways and/or concomitant neurovascular compression. Microvascular decompression is appropriate only when a relevant neurovascular conflict is present and the individual clinical circumstances support surgery. Radiosurgery can provide clinically meaningful pain relief, although recurrence rates may be higher than in classical trigeminal neuralgia.
As treatment options for trigeminal neuralgia have become increasingly diverse, the choice of therapy should always take the patient's individual clinical situation and quality of life into account. It is important to us that patients, their families, and those supporting them understand the condition, the available treatment options, and the considerations relevant to an individual treatment decision.
Our team is committed to ensuring that you feel well cared for from your first contact with the ERCM. For treatment enquiries, please use our contact form. You may also contact us by telephone during our opening hours or via our social media channels.
Each enquiry is reviewed individually and processed promptly.